SCHEMBL22772826

SCHEMBL22772826

O=C(O)N1CC(Cn2ncc3ncc(-c4ccc(F)c(OC(F)F)c4)nc32)OC1=O

nearest known ligand 0.63

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ GRIN2B Q13224 20/20 0.63
▸ GRIN1 Q05586 7/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22772830 0.90 GRIN2B (0.59) GRIN2BGRIN1
SCHEMBL22772841 0.82 GRIN2B (0.59) GRIN2BGRIN1
Hydrochloric Acid SCHEMBL22772871 0.82 GRIN2B (0.59) GRIN2BGRIN1
Hydrochloric Acid SCHEMBL29465739 0.82 GRIN2B (0.59) GRIN2BGRIN1
SCHEMBL22787230 0.81 GRIN2B (0.79) GRIN2B
SCHEMBL22772838 0.77 GRIN2B (1.00) GRIN2BGRIN1
SCHEMBL22772845 0.77 GRIN2B (1.00) GRIN2BGRIN1
SCHEMBL22772827 0.75 GRIN2B (1.00) GRIN2BGRIN1
SCHEMBL29465733 0.75 GRIN2B (1.00) GRIN2BGRIN1
SCHEMBL22772867 0.75 GRIN2B (1.00) GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11993587-B2 Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2024-05-28 — — US disclosed
EP-3983413-A1 SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2022-04-20 — — EP disclosed
US-11214563-B2 Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2022-01-04 — — US disclosed
WO-2020249802-A1 SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-12-17 — — WO disclosed
US-20200392113-A1 SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-12-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11214563-B2 Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators GRIN2B, GRIN2A, GRIN2C GRIN2B 1/4885GRIN1 5/4885
US-20200392113-A1 SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN2C GRIN2B 1/4885GRIN1 5/4885
US-11993587-B2 Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators GRIN2B, GRIN2A, GRIN2C GRIN2B 1/4885GRIN1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback